.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Healthtrust
AstraZeneca
Cipla
UBS
Chinese Patent Office
Novartis
Merck
McKinsey
Julphar

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,943,572

« Back to Dashboard

Which drugs does patent 7,943,572 protect, and when does it expire?


Patent 7,943,572 protects AFREZZA and is included in one NDA.

This patent has fifty-eight patent family members in seventeen countries.

Summary for Patent: 7,943,572

Title:Superior control of blood glucose in diabetes treatment
Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
Inventor(s): Cheatham; Wayman Wendell (Columbia, MD), Boss; Anders Hasager (Princeton, NJ)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:11/278,381
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribePULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribePULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribePULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,943,572

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,006,175Potentiation of glucose elimination► Subscribe
6,444,226 Purification and stabilization of peptide and protein pharmaceutical agents► Subscribe
9,801,925Potentiation of glucose elimination► Subscribe
8,889,099Methods and compositions for delivering peptides► Subscribe
7,943,178Methods and compositions for delivering peptides► Subscribe
8,389,470Methods and compositions for delivering peptides► Subscribe
7,648,960Method for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles► Subscribe
6,652,885 Purification and stabilization of peptide and protein pharmaceutical agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,943,572

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2012203626► Subscribe
BrazilPI0608271► Subscribe
Canada2377204► Subscribe
Canada2601860► Subscribe
China101151047► Subscribe
Cyprus1112441► Subscribe
Cyprus1115766► Subscribe
Denmark1808438► Subscribe
Cyprus1117668► Subscribe
Denmark1909826► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Moodys
Cipla
Chubb
McKesson
Chinese Patent Office
Healthtrust
Queensland Health
Dow
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot